2 Einträge von mit dose countries
clinicalodyssey.com
Datum der Indexierung 03.05.2024 22:10:46
Subdomain:
extern (outbound) Link/Domain 2 in .clinicalodyssey.com
intern (inbound) Link/Domain .clinicalodyssey.com
Alle Links in alle Links in .clinicalodyssey.com
Kombination Keywords measles organ | with joyworks | clinical systems | virus subscribe | your contact | vaccines transmission | dose disease | first administered | about areas | odyssey months |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
doses as the standard for all national immunization programs for children. In countries with low-level measles virus transmission, the first routine dose is administered at 12 months of age or older; and the second dose can be administered at 15–18 m countries with low-level measles virus transmission, the first routine dose is administered at 12 months of age or older; and the second dose can be administered at 15–18 months of age or at school entry. In countries with ongoing
Text Inhalt Text aus URL
Log Metriken 12459
Subdomain:
extern (outbound) Link/Domain 2 in .clinicalodyssey.com
intern (inbound) Link/Domain .clinicalodyssey.com
Alle Links in alle Links in .clinicalodyssey.com
Kombination Keywords measles organ | with joyworks | clinical systems | virus subscribe | your contact | vaccines transmission | dose disease | first administered | about areas | odyssey months |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
doses as the standard for all national immunization programs for children. In countries with low-level measles virus transmission, the first routine dose is administered at 12 months of age or older; and the second dose can be administered at 15–18 m countries with low-level measles virus transmission, the first routine dose is administered at 12 months of age or older; and the second dose can be administered at 15–18 months of age or at school entry. In countries with ongoing
Text Inhalt Text aus URL
Log Metriken 12459
www.cslbehring.ch
Datum der Indexierung 04.10.2024 23:31:04
erkannte Namen Gene Therapy | Emmanuelle Lecomte | Isabelle Dahinden | Maria Tortoreto | Asia Pacific |
weitere Namen in www.cslbehring.ch 5
Subdomain:
extern (outbound) Link/Domain 8 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Swissmedic Approval for HEMGENIX®
Kombination Keywords patients rare | hemgenix this | factor from | hemophilia people | with gene | treatment disease | that therapy | behring your | bleeding more | switzerland global |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
dose treatment option that allows people living with hemophilia B to produce their own factor IX, which can lower the risk of bleeding. The approval is based on results from the ongoing Phase III HOPE-B trial, the largest gene therapy trial in hemoph countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For mor
Text Inhalt Text aus URL
Log Metriken 86111
erkannte Namen Gene Therapy | Emmanuelle Lecomte | Isabelle Dahinden | Maria Tortoreto | Asia Pacific |
weitere Namen in www.cslbehring.ch 5
Subdomain:
extern (outbound) Link/Domain 8 in www.cslbehring.ch
intern (inbound) Link/Domain www.cslbehring.ch
Alle Links in alle Links in www.cslbehring.ch
HTML Description Swissmedic Approval for HEMGENIX®
Kombination Keywords patients rare | hemgenix this | factor from | hemophilia people | with gene | treatment disease | that therapy | behring your | bleeding more | switzerland global |
Alle Keywords (Suchwörter) Liste aller Einträge
Textauszug aus Quelle
dose treatment option that allows people living with hemophilia B to produce their own factor IX, which can lower the risk of bleeding. The approval is based on results from the ongoing Phase III HOPE-B trial, the largest gene therapy trial in hemoph countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For mor
Text Inhalt Text aus URL
Log Metriken 86111